Edgar Wachenheim III's Top Holdings: March 31, 2026 Portfolio Analysis
Greenhaven Associates' Edgar Wachenheim III held significant positions in consumer cyclical, industrials, and healthcare stocks as of March 31, 2026.
As of March 31, 2026, Edgar Wachenheim III, managing director at Greenhaven Associates, maintained a substantial portfolio with a total value of $5.98 billion. His top holdings, representing approximately 67.12% of the total portfolio, were concentrated in consumer cyclical, industrials, and healthcare sectors, showcasing a strategic focus on growth-oriented industries.
General Motors Co (GM) stands as the largest holding in Wachenheim's portfolio, accounting for 15.37% of the total value. The position saw a slight reduction in March 2026, with a 17.48% decrease in shares compared to the previous period.
Lennar Corporation (LEN) is the second-largest holding, representing 15.21% of the portfolio. Wachenheim increased his stake in this homebuilding company by 5.33% during the prior period.
Toll Brothers, Inc. (TOL) and PulteGroup Inc. (PHM) both feature prominently in the consumer cyclical sector, holding allocations of 12.69% and 10.65%, respectively. Wachenheim trimmed his position in Toll Brothers by 0.75% but saw a minimal decrease of 0.67% in PulteGroup shares.
D R Horton, Inc. (DHI) represents another significant position in the homebuilding sector, accounting for 7.84% of the portfolio. The stake experienced a negligible 0.49% reduction.
Oshkosh Corp (OSK) is the largest holding in the industrials sector, representing 6.14% of the portfolio. Wachenheim maintained the position with a slight increase of 0.39% in shares.
The investor's portfolio includes exposure to technology and healthcare sectors through Arrow Electronics Inc. (ARW) and Avnet Inc. (AVT), both holding 4.48% and 3.98% allocations, respectively. Wachenheim reduced his stake in both companies by 0.22% and 0.21% during the prior period.
Baxter International Inc. (BAX) and SLB LTD (SLB) round out the top ten holdings, representing 3.96% and 3.95% of the portfolio, respectively. Wachenheim significantly increased his stake in Baxter by 33.8% while maintaining a minimal position in SLB.